Campbell, Noll L.Skaar, Todd C.Perkins, Anthony J.Gao, SujuanLi, LangKhan, Babar A.Boustani, Malaz A.2016-06-282016-06-282015Campbell, N. L., Skaar, T. C., Perkins, A. J., Gao, S., Li, L., Khan, B. A., & Boustani, M. A. (2015). Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clinical Interventions in Aging, 10, 269–275. http://doi.org/10.2147/CIA.S659801178-1998https://hdl.handle.net/1805/10205OBJECTIVE: To determine the frequency of pharmacogenomic variants and concurrent medications that may alter the efficacy and tolerability of acetylcholinesterase inhibitors (AChEIs). MATERIALS AND METHODS: A multisite cross-sectional study was carried out across four memory care practices in the greater Indianapolis area. Participants were adults aged 65 years and older with a diagnosis of probable or possible Alzheimer's disease (AD) (n=105). Blood samples and self-reported medication data were collected. Since two of the three AChEIs are metabolized by cytochrome P450 (CYP)-2D6, we determined the frequency of functional genetic variants in the CYP2D6 gene and calculated their predicted CYP2D6-activity scores. Concurrent medication data were collected from self-reported medication surveys, and their predicted effect on the pharmacokinetics of AChEIs was determined based on their known effects on CYP2D6 and CYP3A4/5 enzyme activities. RESULTS: Among the 105 subjects enrolled, 72% were female and 36% were African American. Subjects had a mean age of 79.6 years. The population used a mean of eight medications per day (prescription and nonprescription). The CYP2D6 activity score frequencies were 0 (3.8%), 0.5 (4.8%), 1.0 (36.2%), 1.5-2.0 (51.4%), and >2.0 (3.8%). Nineteen subjects (18.1%) used a medication considered a strong or moderate inhibitor of CYP2D6, and eight subjects (7.6%) used a medication considered a strong or moderate inhibitor of CYP3A4/5. In total, 28.6% of the study population was predicted to have reduced activity of the CYP2D6 or CYP3A4/5 enzymes due to either genetic variants or concomitant medications. CONCLUSION: Both pharmacogenetic variants and concurrent drug therapies that are predicted to alter the pharmacokinetics of AChEIs should be evaluated in older adults with AD. Pharmacogenetic and drug-interaction data may help personalize AD therapy and increase adherence by improving tolerability.en-USAttribution-NonCommercial 3.0 United StatesAlzheimer Diseasedrug therapyCholinesterase InhibitorsPharmacokineticstherapeutic useCytochrome P-450 CYP2D6GeneticsPrecision MedicineArticle